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HIGHLIGHTS
Although canine cognitive dysfunction syndrome is an
underdiagnosed  disease,  research  in  this  field  is
growing and clinical advances have been made, and as
a result, this syndrome is becoming more common. 
CCD causes a decline in quality of life for both the dog
and the owner. 
It is necessary to improve the overall knowledge about
this condition in order to make an early diagnosis to
slow its progression.
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Abstract
Canine Cognitive Dysfunction Syndrome (CCD) is a neurodegenerative disease affecting aging dogs. CCD is 
an underdiagnosed disease that involves at least 14% of geriatric dogs, but apparently less than 2% of 
diseased dogs are diagnosed. There are several physiopathological similarities between Alzheimer disease 
(AD) and CCD, developing amyloid-β deposits in brain parenchyma and blood vessels, brain atrophy and 
neuronal loss. The clinical signs lead to behavioural changes. They are unspecific and could appear as soon 
as seven years of age, but are more relevant in senior dogs. The abnormal behaviour could be classified 
following the acronym DISHA: Disorientation in the immediate environment; altered Interactions with 
humans and other animals; Sleep-wake cycle disturbances; House-soiling; and changes in Activity levels. 
There is no specific diagnostic test or biomarker to demonstrate the presence of CCD; therefore, it is often 
assessed by ruling out other diseases that may cause similar behavioural changes. Veterinarians have to be 
able to make an accurate account of veterinary history asking for abnormal behaviour that could be 
misreported by the owners. CCD is a neurodegenerative disorder that cannot be cured. It is possible to delay 
the progression of the clinical signs and improve the quality of life of patients, but like in AD, the 
progression of the illness will depend on the individual. There are three treatment pathways, which could be 
used in combination: drug therapy to improve cognition and reduce anxiety, antioxidant diet and 
nutraceutical supplements to reduce the progression of the illness, and finally, environmental enrichment to 
maintain brain activity. The aim of this review article is to contribute to the knowledge of the illness, 
presenting recent advances in the pathophysiology, diagnosis and treatment of the disease.
This  review  article  presents  the  recent  advances  in
diagnosis and treatment of the illness and contributes
to our understanding of the syndrome.
 1. INTRODUCTION
Aging is a natural process that affects every cell of the
body  including  neurons.  As  animals  age,  different
illnesses  that  could  compromise  their  quality  of  life
(QOL)  appear.  Both  human  and  veterinary  medicine
have  increased  the  longevity  of  people  and  pets,
respectively.  Therefore,  the  development  of
neurodegenerative diseases is becoming more frequent
(Landsberg  et  al.  2012).  The  relationship  between
clinical  signs  and  physiopathology  in  Alzheimer
disease  (AD)  and  canine  cognitive  dysfunction
syndrome (CCD)  makes  the  dog an excellent  animal
model for the understanding of AD (Cummings et al.
1996; Fast et al. 2013). 
Canine  CCD  is  an  age-related  neurodegenerative
illness that generally affects dogs over seven years of
age and is characterized by gradual cognitive decline
and  increasing  brain  disorders  (Landsberg  2005;
Landsberg et al. 2011, Laflamme 2012; Nagasawa et al.
2014). The age of onset of the clinical signs depends on
the  breed  according  to  their  life  span  differences.
Despite  the  fact  that  the  prevalence  did  not  differ
between breeds (Salvin et al. 2006), smaller breeds have
a  longer  life  span  than  the  larger  ones,  thus  it  is
possible  to  recognize  more  clinical  signs  of  CCD  in
small breeds (Vite and Head 2014; Schmidt et al. 2015).
CCD prevalence is reported to range from 14% (Salvin
et al. 2006) to 22% (Azkona et al. 2009). In a study of
497 dogs from eight to 19 years, Salvin and colleagues
(2006)  recruited  owners  to  an  internet-based  survey.
This  84-item  questionnaire  was  used  to  estimate  the
incidence of CCD. The survey included questions about
activity levels, behaviour, phobias, eating and drinking
habits, management and health. They found an overall
prevalence of 14.2%, but it could be up to 41% in dogs
older than 14 years. Consequently, Salvin et al. (2006)
suggested  that  the  prevalence  seems  to  be  higher  in
older dogs. Azkona et al. (2009) used 325 geriatric dogs
to  describe  the  prevalence  of  the  disease.  They used
phone  interviews  to  gather  information  about  four
behavioural categories related to cognitive impairment:
sleep-wake  cycles,  social  interaction,  learning  and
house training and signs of disorientation.  Regardless
of breed, the prevalence seems to be higher in females
than in males. Prevalence is also reportedly higher in
neutered  males,  than  entire  males  (Landsberg  et  al.
2011). 
There are numerous nonspecific clinical signs of CCD,
like  disturbance  of  the  sleep/wake  cycle,  changes  in
social  interactions  with  people,  urinary  and  faecal
incontinence,  disorientation  in  well-known  places,
hearing loss, and excessive vocalization among others
(Dewey 2008, p. 123; Nagasawa et al. 2014). Because of
these  nonspecific  clinical  signs  and  the  fact  that  the
owners usually think that the behavioural changes of
their  pets  are  due  to  the  typical  changes  caused  by
aging, it is often difficult to make an accurate and early
diagnosis of CCD. Recent studies have focused on the
development  of  diagnostic  tools  based  on  food
searching  or  problem  solving  tasks.  There  are  also
recent  advances  in  the  knowledge  of  the
physiopathology  of  the  aging  brain,  and  about  new
treatments  with  drugs,  diets  and  environmental
enrichment  (Landsberg  et  al.  2011;  Laflamme  2012;
Landsberg et  al.  2012;  González-Martínez et  al.  2013;
Vite and Head 2014). 
It  is  documented  that  cognitive  impairment  in  older
dogs can be a challenging problem, both for the animal
and for  the  owners.  The high percentage of geriatric
cognitive  impaired  dogs  and  the  reduction  in  dog’s
QOL suggest a better knowledge of CCD is necessary
(Landsberg  et  al.  2011).  The aim of  this  review is  to
compile  the  recent  advances  in  physiopathology,
diagnosis and treatment options for CCD. 
2. PHYSIOPATHOLOGY
There are several  histopathologic similarities between
human brains affected by AD and dog brains suffering
from CCD. In both diseases, the aged brain develops an
abnormal β-amyloid (Aβ) deposit in brain parenchyma
and  blood  vessels,  neuronal  loss  and
hyperphosphorylated tau protein (HTP) (Schmidt et al.
2015). Aβ is a protein produced by the degradation of
amyloid precursor protein (APP) (Vite and Head 2014).
In the aging dog brain the deposits present as diffuse
plaques  in  cortical  regions,  and tend to  appear  from
eight  years  of  age  (Landsberg  et  al.  2012;  Fast  et  al.
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2013; Schmidt et al. 2015). The prefrontal cortex is the
first area affected, followed by the temporal cortex, the
hippocampus and the occipital cortex. 
Regardless  of  position,  the  amount  and extent  of  Aβ
deposits  are  correlated  with  the  degree  of  cognitive
impairment and leads to oxidative damage (Fast et al.
2013; Vite and Head 2014; Romanucci and Della Salda
2015;  Schmidt  et  al.  2015).  In  addition,  a  local
inflammatory  reaction  has  been  found  around  Aβ
deposits in both humans and dogs (Schmidt et al. 2015).
Aβ deposits are also found in brain blood vessels in AD
and CCD. Cerebrovascular amyloid angiopathy (CAA)
is related to cognitive impairment in both humans and
dogs (Romanucci and Della Salda 2015). The occipital
cortex  is  the  main  affected  area  and  these  deposits
could  disrupt  the  blood-brain-barrier  and  cause
microhemorrhages (Vite and Head 2014).  
The  brain  consumes  20% of  the  total  body´s  oxygen
and is very susceptible to oxidative damage due to the
high percentage of polyunsaturated fatty acids and the
lower levels of endogenous antioxidant activity (Head
2008).  The  metabolic  process  of  the  cells  causes  the
release  of  reactive  oxygen species  (ROS) that  lead to
oxidative damage to proteins,  lipids,  DNA and RNA
(Head 2008).  The production of ROS depends on the
mitochondria  (Romanucci  and  Della  Salda  2015);
therefore, a mitochondrial dysfunction could cause the
overproduction  of  ROS.  This,  together  with  a  lesser
activity of antioxidants enzymes in the aged canine or
in  the  neurodegenerative  disease  could  lead  to
oxidative  damage,  Aβ  deposition  and  cognitive
dysfunction (Dowling and Head 2012; Davis and Head
2014; Vite and Head 2014; Romanucci and Della Salda
2015).  
Iwata  and  colleagues  (2005)  described  the  Aβ
catabolism  and  found  that  an  imbalance  between
production  and  clearance  of  Aβ  could  provoke  the
accumulation  of  Aβ  in  the  brain.  Aβ  could  be
eliminated  by  two  mechanisms:  active  transport
through  the  blood  brain  barrier  and  enzymatic
degradation  by  peptidases  like  neprilysin  (NPL)
(Canudas et al. 2014). In the brain areas in which the
Aβ deposits  are  more  frequent,  NPL is  expressed  in
lower  levels  than  areas  with  lesser  amounts  of  Aβ
accumulation (Reilly 2001). Canudas et al. (2014) found
that the expression of NPL was five times higher in the
cognitive  unimpaired  dogs  than  in  the  cognitive
impaired dogs.  This suggests  that  NPL could protect
against CCD. 
In  a  recent  study,  Schmidt  and  colleagues  (2015)
provided  the  first  description  and  quantification  of
pyroglutamyl  Aβ  (pE3Aβ)  in  the  canine  brain.  The
pE3Aβ  is  a  peptide  derived  from  Aβ  peptides  that
suffers  from  N-terminal  truncation  and  subsequent
cyclization  of  N-terminal  glutamate  (Hartlage-
Rübsamen  et  al.  2011).  This  peptide  encourages  the
accumulation of Aβ facilitating the onset of CCD. The
ventral  hippocampus  and  entorhinal  cortex  of  aged
dogs’  brain  seem  to  be  more  affected  by  pE3Aβ
deposits; the location of these deposits correlates with
clinical  signs  of  CCD,  such  as  disorientation  and
memory loss (Schmidt et al. 2015). 
In human medicine there is a documented relationship
between HTP and cytotoxicity of Aβ deposits (Schmidt
et al. 2015). In a study by Schmidt et al. (2015), only one
out of 24 dogs displayed formation of neuro fibrillary
tangles of HTP. Therefore, research reinforces that the
Aβ  deposits  and  the  HTP  are  two  independent
processes in the aged canine brain (Head 2002; Schmidt
et al. 2015). 
Other  physical  pathological  changes  in  CCD  are
different  processes  related  to  brain  atrophy,  such  as:
thinning of  the  cerebral  cortex  and subcortical  white
matter;  widened  sulci;  marked  ventriculomegaly;
meningeal  calcification;  demyelination;  increased
lipofuscin;  neuroaxonal  degeneration;  and  apoptotic
bodies (Laflamme 2012; Landsberg et al. 2012; Vite and
Head 2014). 
Brain atrophy may be due to neuronal loss. In the brain
of dogs,  new neurons are produced continually from
progenitor cells placed in specific brain regions such as
the dentate gyrus of the hippocampus.  In a previous
study, Siwak-Tapp and colleagues (2007) found a 90%
to 96% decline in neurogenesis in the hippocampus of
aged beagles.  This  suggests  that  the neuronal  loss in
the brain atrophy process could be related to cognitive
performance  in  aged  dogs.  According  to  Pan  and
colleagues (2012),  reduction in neurogenesis could be
caused  by  the  lesser  extent  of  progenitor  cell
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proliferation and the shorter survival  of  the neurons.
Alterations  in  neurochemical  systems  such  as  the
cholinergic,  glutaminergic,  dopaminergic  and
GABAergic  neurotransmitter  systems,  with  reduced
neuronal  and  synaptic  function  have  also  been
observed (Landsberg et al. 2012). 
All these brain changes could contribute to the primary
clinical  signs of  CCD like  memory loss,  alteration in
spatial  orientation,  and  alteration  in  REM  sleep
(Landsberg et al. 2012).         
3. CLINICAL SIGNS
When  dogs  are  aged  seven  years  old  or  older,  we
consider  that  they  are  senior  canines  at  risk  of
developing an age-related health  problem (Laflamme
2012).  Although clinical  signs of CCD may appear at
seven years old, these become more relevant as dogs
age.  Nevertheless,  owners often overlook CCD signs,
dismissing  them  as  normal  aging.  Delay  in  the
recognition of  cognitive  impairment  could  be  due  to
the fact that the owners sometimes do not realize subtle
signs of behavioural changes or associate the changes
with the advanced age of their pets. It is very important
to  consider  the  complete  veterinary  history  and  to
question  dog  owners/handlers  about  behavioural
changes  that  could  be  indicative  of  cognitive
impairment when diagnosing the condition (Landsberg
et al. 2012).
Vite and Head (2014) describe a case of CCD in an 11
year  old  female  Border  Collie  used  on  a  farm  as  a
livestock herding dog. According to her owner, when
the  dog  reached  11  years,  she  was  almost  deaf,  had
begun to  show some confusion  with  commands  and
had lost interest in pursuing sheep. Over the next two
years  the  hearing loss  progressed and her  behaviour
was  perceived  by  the  owner  as  stubbornness.  She
started  to  stalk  the  other  resident  dog  and  began
pacing,  panting,  and showing  signs  of  anxiety  when
her owner was not at home. She was no longer making
eye  contact  with  people  and  sometimes  she  lost  the
route that she had previously followed daily. She was
euthanized at 14 years old and an extensive diffuse Aβ
deposit was found in the dentate gyrus and prefrontal
cortex. 
All  the  physiopathological  changes  in  CCD  cause
several  clinical  signs that  are  classified following the
acronym  DISHA  (Table  1):  Disorientation  in  the
immediate  environment,  altered  interactions  with
humans  and  other  animals,  sleep-wake  cycle
disturbances,  house-soiling,  and  changes  in  activity
levels (Manteca 2011; González-Martínez et al. 2013). In
addition,  it  is  important  to  consider  that  there  is
individual  variability  between aged dogs in  terms of
clinical signs for the same pathology (Nagasawa et al.
2014). Despite this, in a study by Mariotti et al. (2009),
aggression was the most reported clinical  sign (53%),
followed by fear and anxiety reported in a much lower
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Table 1. Clinical signs of CCD that can be classified following the acronym DISHA
proportion  of  subjects.  To  summarise,  in  cases  of
suspected  CCD,  it  is  essential  that  the  veterinarian
assesses for clinical signs related to DISHA.
Dogs  with  CCD  may  also  express  signs  of  anxiety;
however, these may also appear with pain or relate to
other  systemic  illnesses.  These  signs  could  be  new
behavioural patterns like eliminating in unusual places
at home, cessation of jumping behaviour when greeting
people,  avoidance  of  the  owner  or  home  residents,
unusual growling or aggressiveness, excessive panting,
yawning, nose licking, or momentary immobilization.
Social alterations related to anxiety, such as decreased
play-time  with  people  and  other  pets,  decreased
interest  in  toys,  altered  quality  of  sleep,  and  hiding
behaviour may also be relevant. When signs of anxiety
appear at night it may pose a significant problem due
to  sleep  disruption  of  the  home  residents,  thus  the
relationship  between  owner  and  pet  may  become
negatively affected (Landsberg et al. 2011).  
Nearly all of the clinical signs in the DISHA suite could
be  confused  with  different  diseases.  In  this  way,
veterinarians  have  to  be  cautious  when  diagnosing
CCD  without  ruling  out  other  pathologies.
Disorientation in the immediate environment may be
caused by hearing loss as a result of aging or chronic
otitis,  visual  loss  because  of  the  development  of
cataracts,  glaucoma  or  retinal  detachment  among
others  (Bernardini  2010,  p.  30,  36).  Changes  in
interactions  with  humans  or  other  animals  could  be
due to some painful illnesses. It is frequent that senior
dogs  developing  arthritis  and/or  arthrosis  are
reluctance to move and play with other dogs, and may
even become aggressive in an attempt to avoid contact
(Nelson and Couto 2009, p. 1121).  Epileptic dogs can
show an abnormal behaviour during the pre- and post-
seizure period (De Risio and Platt, 2014, p.39). 
The allodynia or hypersensitivity to skin pressure due
to  neuropathic  pain  could  also  deteriorate  the
interaction  with  humans.  In  this  case,  when  owners
caress  the  affected  region  the  dog  may  even  yell  or
moan  due  to  pain  (Grubb  2010).  Sleep-wake  cycle
disturbances  and  house-soiling  are  also  related  to
systemic  illnesses,  like  renal  or  hepatic  failure.  The
development  of  acute  or  chronic  kidney  disease  is
common in geriatric dogs. These diseases may provoke
changes to urination patterns, pain and a reduction on
the activity of the dog (Nelson and Couto, p. 491, 617). 
There are several disorders that may change the normal
activity  of  the  dog.  Metabolic  disorders  like
hypothyroidism and hypoadrenocorticism could cause,
among other symptoms,  lethargy,  reluctance to move
and  tendency  to  gain  weight  (Ettinger  and  Feldman
2010).  Cardiovascular  disorders  like  dilated  or
hypertrophic cardiomyopathy, heart blockage or valve
heart disease, among others,  could cause a reluctance
to move or quick fatigue during exercise (Ettinger and
Feldman 2010,).        
To the authors’ knowledge, DISHA constitutes the best
model to explain the clinical signs of CCD since it puts
together the main behavioural changes of a cognitively
impaired dog. Anxiety might be a new letter to add to
the acronym but we consider that all the behavioural
changes of DISHA could cause  some discomfort  and
anxiety to the dog.           
4. DIAGNOSIS
Salvin  and  colleagues  (2011)  conducted  an
epidemiological  study  surveying  497  dogs  ranging
from eight to 19 years. The overall prevalence of CCD
was  calculated  based  on  owner  reports  to  be  14.2%;
however,  only  1.9%  had  a  presumptive  diagnosis  of
CCD  from  a  veterinarian.  Underdiagnosis  may  be
frequent due to the lack of a specific diagnostic tool and
the  unspecific  symptoms.  As  commented  previously,
some owners are not able to report subtle behavioural
changes in their pets or may have dismissed them as
typical aging processes. Therefore, veterinarians must
be active in asking about any changes or abnormalities
to  the  dog´s  behaviour,  asking  specifically  for
disorientation in daily life, longer sleeping time along
the day, loss of house training and house-soiling. It is
also important  to  know the normal behaviour  of  the
dog  during  its  life  to  assess  any  potential  abnormal
changes  in  behaviour  due  to  an  underlying  disease.
There are  several  types of  chronic  illnesses  that  may
provoke  changes  in  canine  behaviour.  Orthopaedic
disease  could  cause  pain,  cardiovascular  impairment
may  lead  to  reluctance  to  exercise  and  metabolic
disorders  could  reduce  the  normal  activity  of  the
animal or increase aggressiveness. To ensure accuracy,
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the  diagnosis  of  CCD  should  be  made  following
exclusion of all these diseases (Landsberg et al. 2011).
Therefore, it is necessary to make an exhaustive clinical
exam  (physical,  neurological,  ophthalmologic,
orthopaedic  and  ethological  examination)  to  assess
behavioural  changes  related  to  any  physical  illness
(Landsberg et al. 2012). Intracranial pathologies related
to  behavioural  changes,  such  as  brain  tumours,  are
more frequent in aged dogs. Endocrine disorders could
cause  irritability,  lethargy  and  aggressiveness.
Metabolic disorders like hepatic or renal failure lead to
an altered mentation and house-soiling.  Orthopaedic,
gastrointestinal, urogenital and dermatological diseases
likewise  neuropathic  pain  could  cause  severe  pain
conditions  that  may  provoke  behavioural  changes.
Cardiovascular  diseases  are  related  to  restless
(Landsberg et  al.  2011).  In  addition,  it  is  common to
find two or more of these diseases in geriatric patients.
Knowledge  of  existing  and/or  previous  medications
and  treatments  is  also  important,  and  possible
cognitive  impairment  associated  with  these  drugs
should be ruled out. Steroids have been shown to be
associated  with  changes  to  eating,  drinking  and
urination  as  well  as  nervousness  and  aggression.  In
addition,  pain  medication  can  sometimes  cause
sedation (Landsberg et al. 2012). 
When all  these  pathologies have been ruled out  it  is
important  to  carry  out  an owner-based observational
questionnaire  to  assess  the  cognitive  function  of  the
patient  (González-Martínez  et  al.  2013).  Nielson  and
colleagues  (2001),  carried out  a  study  with  180 dogs
from 11 to 16 years old, using a questionnaire including
items related to four categories of cognitive impairment
(disorientation,  altered  social  interactions,  disturbed
sleep-wake  cycle  and  house  training).  They  assessed
the severity of the cognitive impairment depending on
the number of categories affected and the number of
new behavioural  changes found in  each category.  To
the authors´ knowledge, it could be essential to include
items related to all categories of DISHA in any owner-
based  observational  questionnaire.  Because  there  is
individual  variability  in  the  presentation  of  clinical
signs and, due to the fact that DISHA includes all the
behavioural changes known to be found in a dog with
CCD,  a  questionnaire  based  on  DISHA could  be  an
appropriate diagnostic tool.  
González-Martínez  et  al.  (2013),  searched for  a  more
objective diagnostic procedure than these owner-based
observational  questionnaires.  They  assessed  the
effectiveness of two simple tasks (a food searching task
[FS] and a problem solving task [PS]) administered in a
clinical setting in 87 dogs. They found differences in the
two tasks between the cognitively impaired group and
the  young-middle  aged  group.  The  younger  dogs
comprising  the  second  group  were  able  to  find  and
obtain  the  food  more  quickly  than  their  aged
counterparts  in  the  cognitively  impaired  group.  In
addition, some dogs in the latter group did not even
attempt to search for the food. These assessment tasks
could help in the accurate diagnosis of CCD. 
5. TREATMENT    
It  is  important  for  veterinarians  to  advise  owners  of
dogs  diagnosed  with  CCD  that  it  is  a
neurodegenerative  disorder  that  cannot  be  cured,
although it is possible to delay the progression of the
clinical  signs  and  improve  the  QOL  of  the  dog.
However, as in AD, the advancement of the illness is
dependent  on the  individual  (Landsberg  et  al.  2011).
Current  treatments  tend  to  combine  specific  diets,
environmental enrichment and drugs, obtaining better
success  and  improving  pets´  QOL.  The  sooner
treatment begins, the better the response, therefore it is
important to make an early diagnosis (Landsberg et al.
2012).  
Nutritional Treatment  
In human medicine, there are several studies about the
best  diet  option  for  the  treatment  of  AD.  The
combination of various antioxidants seems to be more
efficacious  as  part  of  the  diet  than  as  a  single
nutraceutical  supplementation  (Dowling  and  Head
2012).  In  veterinary  medicine,  studies  shown that  an
antioxidant  diet,  in  addition  to  some  dietary
supplements, is the best nutritional therapy (Laflamme
2012; Landsberg et al. 2012)(Table2). 
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Initially,  the  nutrition  of  the  pet’s  diet  must  be
evaluated  because  of  the  changes  in  the  nutritional
requirements  associated  with  aging.  Maintenance
energy  requirements  decrease  about  25%  in  dogs
greater  than  seven  years  of  age  and  brain  glucose
metabolism is  also  reduced.  Thus  it  is  mandatory  to
adapt  the  current  diet  to  their  current  nutritional
requirements  (Laflamme  2012).  Dowling  and  Head
(2012)  used  an  antioxidant  diet  formulated  with
vitamins  A,  C  and  E,  L-carnitine,  lipoic  acid,  zinc,
selenium  and  dehydrated  fruits  and  vegetables
(spinach  flakes,  tomatoes,  grape pomace,  carrots  and
citrus pulp in a 1% proportion each). They proved that
reduced  oxidative  stress  leads  to  cognitive  benefits.
They used 48 senior  beagles  divided in four  groups:
two  control  diet  groups,  one  with  and  the  other
without behavioural enrichment (groups 1 and 2), and
other two groups of antioxidant diets with and without
behavioural enrichment respectively (groups 3 and 4).
There were significant improvements over a two week
period related to spatial attention, visual discrimination
and learning ability in the groups fed with antioxidant
diet,  especially  in  the  group  with  environmental
enrichment.  In  addition,  reduced  oxidative  damage
and  increased  endogenous  antioxidant  activity  were
found in groups 3 and 4 in the study. 
Glucose  is  the  main  energy  source  of  neurons.
However,  glucose  metabolism  is  reduced with  aging
and  other  energy  sources  are  needed  to  maintain
neurons´ metabolism (Pan 2011; Laflamme 2012). Fatty
acids derived from MCT could provide up to 20% of
brain energy request. For instance, lactate and ketones
cross  the  blood-brain  barrier  and  serve  as  energy
source (Laflamme 2012; Landsberg et al. 2012). Pan and
colleagues  (2010)  found  significant  improvement  in
cognitive  function  in  dogs  fed  with  medium  chain
triglycerides.  It  has  been  proven  that  diets
supplemented with this type of lipid also reduce levels
of  APP and Aβ deposits  and improve mitochondrial
function  (Taha  et  al.  2009).  Nowadays,  we  can  find
numerous commercial diets containing medium chain
triglycerides  and  antioxidants  such  as  Hill's  Pet
Nutrition  b/d  and  Purina  One  Vibrant  Maturity  7+
Senior.
Due  to  the  possibility  of  two  or  more  concomitant
diseases in senior dogs, often it is not possible to make
changes  in  the  diet.  In  this  case  the  use  of  single
nutraceuticals can be an alternative. Phosphatidylserine
is  a  phospholipid  that  improves  social  interactions,
house  soiling  and  orientation  in  dogs  (Heath  et  al.
2007).  In  a  study  of  aged  beagles  fed  with
phosphatidylserine,  Gingko  biloba,  vitamin  E  and
pyridoxine  an  improvement  in  their  short  term
memory was  observed (Dowling and Head 2012).  S-
adenosyl-L-methionine  increases  endogenous
production  of  antioxidant  glutathione  and  improves
neural  conduction  enhancing  executive  function
(Landsberg et al. 2012). Apoaequorin is a protein that
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Table 2. Diet and dietary supplementation used in CCD (Landsberg et al. 2012). 
seems  to  have  neuroprotection  hallmarks  in  aging
dogs. This protein improves learning and attention in
laboratory trials (Milgram et al. 2011). Docosahexaenoic
acid (DHA) and eicosapentaenoic acid (EPA) are two
polyunsaturated omega-3 fatty acid present in fish oil
that protects the normal neural functions. It is seen that
these fatty acids decrease in AD but there are no data
about  the  beneficial  properties  in  CCD  (Laflamme
2012).  Galán and colleagues (2014) used a nutritional
supplement (Aktivait®, VetPlus) that includes N-acetil
cysteine, a-lipoic acid, Vitamins C and E, L-Carnitine,
Co-enzyme  Q10,  and  polyunsaturated  fatty  acids
(PUFA, phosphatidylserine,  DHA and EPA) in order to
evaluate changes in cerebrospinal fluid after a 50-day-
period  of  treatment.  They  found  increased  levels  of
glucose  and  sodium  and  lower  levels  of  lactate  and
lactate/pyruvate  ratio,  suggesting  an  improvement  in
brain  energy  metabolism  after  dietary
supplementation.    
There are several studies about the beneficial effects of
acetylcarnitine and lipoic acid in AD and CCD. Both of
them enhance mitochondrial function reducing reactive
oxygen species  and also  reducing  oxidative  damage.
Nevertheless,  when  these  two  products  are  used  in
combination with antioxidant substances, the beneficial
effects are not seen (Dowling and Head 2012). Alpha-
casozepine is a biopeptide from milk that is proved to
reduce anxiety  in  rodents  and it  has  been  used as  a
nutraceutical  compound  to  treat  anxiety  and
behavioural disorders like aggression in dogs (Manteca
2011).  
In  summary,  an  antioxidant  diet  combined  with
nutraceuticals (MCT, phosphatidylserine, apoaequorin,
DHA  and  EPA)  improves  cognitive  impairment  in
dogs.  This  treatment  enhances  visuospatial  function,
learning ability and the ability to focus the attention. 
Environmental Enrichment
It has been demonstrated that behavioural enrichment
is protective against neuron loss in the hippocampus of
dogs, improving all DISHA parameters (Dowling and
Head  2012).  The  enrichment  has  to  include  physical
exercise,  social  interactions  and  cognitive  training
(Romanucci and Della Salda 2015). Mental activity is an
important  component  to  maintain  a  good  QOL.
Effective  strategies  to  increase  the  attention  of
cognitively  impaired  dogs  include  the  use  food/treat
puzzle toys,  walks in new environments and to play
games such as fetch and chase. In using environmental
enrichment, it is also important to improve the comfort
of the pet.  New odour,  tactile  and sound cues could
help the dog to orientate in the environment. If there is
an increase in the urine frequency, it may be necessary
to increase the number of walks or to put a toilet area
inside home (Landsberg et  al.  2012).  When there are
problems  of  night  time  waking  and  anxiety,  it  is
important to improve dog´s sleeping patterns. Owners
should pet  the dog when it  is  resting in  its  sleeping
area,  turn  off the  TV,  reduce  noises  and intensity  of
lights during the night, and place the dog´s bed in its
preferred resting area. A useful routine to enhance the
sleeping time is to schedule a physical activity such as
game playing, or a long walk to tire the dog, before to
the dog’s rest time (Landsberg et al. 2011). 
Drug Therapy
The aim of the drug therapy is to restore the natural
brain  function  and  to  slow  the  progression  of  the
illness.  Due to the fact that an inflammatory reaction
around Aβ deposits exists, it has been proposed the use
of  anti-inflammatory  drugs  like  carprofen
(4,5mg/kg/24h) (Dewey 2008, p. 126). There are several
medications for the treatment of CCD (see Tables 3 and
4 for the main and complimentary drugs used in the
treatment of CCD respectively). 
Traditionally, the three drugs selegiline, nicergoline and
propentofylline,  have  been  used  for  the  treatment  of
CCD.  They confer  beneficial  effects  in  activity levels,
improving catecholamines´ levels in the cortex and also
the  blood  flow  to  the  brain.  Propentofylline  also
increases  spatial  attention  and  it  is  effective  treating
dullness,  lethargy and depression;  whereas  selegiline
also enhances social interactions and sleep-wake cycles
(Landsberg et al. 2012).  However it is not possible to
enhance all the DISHA categories by using these drugs
alone (Landsberg et al. 2012).
There are other drugs such as adrafanil and modafinil,
two  noradrenergic-enhancing  drugs,  that  improve
locomotion and learning in dogs (Dewey 2008, p. 126).
Inagawa  and  colleagues  (2005)  found  that  γ-
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aminobutyric acid (GABA) improves QOL of cognitive
impaired  dogs.  Different  behavioural  changes  like
whines,  barks during the night  and when the dog is
home alone, wandering, and sleeping patterns were all
effectively/moderately alleviated with the use of a test
preparation containing GABA. A GABA-ergic drug that
could be used for the treatment of CCD is gabapentin
(Dewey 2008, p. 126; Landsberg et al. 2012).  A recent
study by Nagasawa and colleagues (2014) showed that
N-acetyl-D-mannosamine (ManNAc) alleviates clinical
signs of CCD. Four out of the five dogs treated with
ManNAc showed a permanent improvement in sleep
quality.
To the authors’ knowledge, selegiline is the most useful
drug in treating CCD (Jaggy 2010, p.485), however it is
necessary to combine this with complimentary therapy
in  order  to  enhance  all  the  behavioural  changes
associated  to  the  physiopathology  of  the  syndrome.
Benzodiazepines  are  useful  to  treat  sleep-wake  cycle
disturbances and anxiety because of their sedative and
short-acting anxiolytic effects (Landsberg et  al.  2011).
These  substances  are  often  used  to  treat  fears  and
phobias  and  can  also  help  the  dog  to  sleep  better.
Phenobarbital,  diphenhydramine  and  trazodone  may
also  be  used  for  sleep  support  due  to  their  sedative
effect.  It  is  recommended  these  drugs  be  given  30
minutes before sleeping (Landsberg et al. 2011). 
Other clinical signs related to anxiety, such as noise and
night phobias and separation anxiety, could be treated
with buspirone, fluoxetine or tricyclic antidepressants.
Nevertheless,  the  anticholinergic  effects  need  to  be
taken into consideration (Jaggy 2010, p. 487, Landsberg
et al. 2011).
There  is  some  controversy  surrounding  the  use  of
statins  for  the  treatment  of  CCD.  Atorvastatin  is  a
selective  inhibitor  of  HMG-CoA reductase  that  acts
lowering cholesterol levels and reducing Aβ deposits.
This drug has been used in human medicine reducing
the risk of developing AD. However, it has been shown
that  atorvastatin  reduces  levels  of  coenzyme  Q10
(CoQ10),  a  mitochondrial  electron  transporter  and  a
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powerful cellular antioxidant. Low levels of CoQ10 in
the  brain  could  be  related  to  cognitive  impairment
(Martin et al. 2011). As seen in Martin and colleagues
(2011) study, serum CoQ10 was significantly lower in
atorvastatin-treated dogs.  Therefore, more studies are
needed to clarify the relationship between atorvastatin
and  CoQ10  and  to  determine  the  effectiveness  of  a
combined treatment with atorvastatin and CoQ10 oral
supplementation.
In  a  recent  study,  Bosch  and  colleagues  (2015)
developed  an  anti-Aβ  immunotherapy  that  modified
the equilibrium between soluble  and insoluble Aβ in
aged canines.  In  the  immunized  group,  the  amyloid
plaques were smaller and less compact than those of
the unimmunized group.          
Among  natural  products  that  could  help  reduce
anxiety  and improve QOL for  canine  with  CCD,  the
valerian  root,  honokiol,  berberine  extracts,  α-casein,
suntheanine, lavender essential oils, and a pheromone
collar have been shown to be useful (Dewey 2008, p.
126; Landsberg et al. 2011).    
To conclude, it is important to emphasise the need to
use  a  combined  therapy  to  treat  CCD.  According  to
DISHA, D and H parameters  are  specially  improved
with the nutritional treatment using an antioxidant or
MCT enriched diet (I and A parameters could be also
improved with an alpha-casozepine and S-adenosyl-L-
methionine  supplementation,  respectively).  S  and  A
parameters  and anxiety  could  be  enhanced by using
different  drugs.  Finally,  environmental  enrichment
helps in  all  the  DISHA categories  but  especially  in  I
parameter.  The  stimulation  of  mental  activity  along
with physical  exercise,  cognitive  training and games,
improves  social  interactions  with  both  humans  and
other animals.      
SUMMARY     
CCD is an underdiagnosed neurodegenerative disease
that  affects  a  high  proportion  of  the  aged  canine
population.  The  number  of  unspecific  clinical  signs
makes it difficult to diagnose and there are no specific
biomarkers  of  the  illness.  Therefore,  the  veterinarian
has to rule out other diseases and medical treatments
that  may  cause  behavioural  changes  associated  with
the acronym DISHA. There are numerous choices for
the treatment of CCD but some of these require more
research to clarify their effectiveness. However, the best
treatment option we currently know of is to combine
drug  and  nutritional  therapy  with  an  environmental
enrichment program to improve the QOL of both the
owners and the canines.  
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